Analytical Data
-
Gene name
MYCL1
- Application
-
Alternative Names
MYCL1；BHLHE38；LMYC；MYCL1；Protein L-Myc
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12524
-
Expression Region
1-364aa
-
AA Sequence
MDYDSYQHYF YDYDCGEDFY RSTAPSEDIW KKFELVPSPP TSPPWGLGPG AGDPAPGIGP PEPWPGGCTG DEAESRGHSK GWGRNYASII RRDCMWSGFS ARERLERAVS DRLAPGAPRG NPPKASAAPD CTPSLEAGNP APAAPCPLGE PKTQACSGSE SPSDSENEEI DVVTVEKRQS LGIRKPVTIT VRADPLDPCM KHFHISIHQQ QHNYAARFPP ESCSQEEASE RGPQEEVLER DAAGEKEDEE DEEIVSPPPV ESEAAQSCHP KPVSSDTEDV TKRKNHNFLE RKRRNDLRSR FLALRDQVPT LASCSKAPKV VILSKALEYL QALVGAEKRM ATEKRQLRCR QQQLQKRIAY LTGY
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYCL1, a member of the MYC proto-oncogene family, encodes a transcription factor that plays a pivotal role in cell growth, differentiation, and apoptosis. Aberrant expression of MYCL1 is implicated in various cancers, particularly in small cell lung cancer (SCLC) and neuroblastoma, where it acts as an oncogene promoting tumor progression. The necessity of MYCL1 in cellular processes and its association with malignancies have propelled research towards understanding its structure, function, and potential as a therapeutic target. Recombinant MYCL1 protein studies have emerged as a crucial approach to decipher its biological mechanisms and interactions with other cellular proteins. By utilizing advanced expression systems, researchers can produce MYCL1 in sufficient quantities to conduct functional assays, enabling the exploration of its role in oncogenesis and its interactions with small molecule inhibitors or other therapeutic agents. Such research endeavors aim to unravel MYCL1's contribution to tumor biology, potentially leading to innovative strategies for cancer treatment and the development of specific inhibitors targeting MYCL1 expression or activity. Understanding the dynamics of MYCL1 as a recombinant protein lays the groundwork for future studies seeking to elucidate its exact mechanisms of action and therapeutic implications in various cancers.
